Cangrelor

Overview

Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an active drug not requiring metabolic conversion therefore providing a rapid onset and offset of action. Cangrelor was approved by the FDA in June 2015 for intravenous application.

Background

Indication

For use as an adjunct to percutaneous coronary intervention (PCI) for reducing the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients in who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.

Associated Conditions

Coronary Revascularization
Peri-procedural Myocardial Infarction
Thrombosis (Stent Thrombosis)

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Cangrelor on Top of AnticoagUlation in Patients with MyocaRdial Infarction-related Cardiogenic Shock/Cardiac Arrest ReceiVIng VA-ECMO	2025/01/27	NCT06792643	Phase 2	Recruiting	IRCCS San Raffaele
Effects of Cangrelor on MIcRovAscular Disfunction During Elective Percutaneous CORonary Intervention	2023/10/18	NCT06089577	Phase 4	Recruiting	Federico II University
Intravenous CAngrelor in High-bleeding Risk Patients Undergoing percutaneouS Coronary Intervention (ICARUS) Registry	2022/08/18	NCT05505591	N/A	UNKNOWN	Universita degli Studi di Genova
Evaluation of Myocardial Reperfusion After Primary PCI in Patients With High Platelet Reactivity Treated by Cangrelor or Not	2021/06/16	NCT04927949	Phase 4	Completed	University Hospital, Caen
Pharmacodynamic Effects of Cangrelor in ACS or CCS Patients Undergoing PCI (POMPEII Registry)	2021/03/10	NCT04790032	N/A	Recruiting	Federico II University
Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCI	2020/12/16	NCT04668144	Phase 4	Completed	University of Florida
REperfusion With P2Y12 Inhibitors in Addition to mEchanical thRombectomy for perFUsion Imaging Selected Acute Stroke patiEnts	2020/12/14	NCT04667078	Phase 3	Recruiting	Fondation Ophtalmologique Adolphe de Rothschild
PD and PK Profiles of Switching Between Cangrelor and Ticagrelor Following Ticagrelor Pre-treatment	2020/11/18	NCT04634162	Phase 4	Completed	University of Florida
Dutch Cangrelor Registry	2019/10/24	NCT04138641	N/A	Completed	Isala
Cangrelor in Comatose Survivors of OHCA Undergoing Primary PCI	2019/07/02	NCT04005729	Phase 4	Completed	University Medical Centre Ljubljana

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
KENGREAL	Chiesi USA, Inc.	10122-620	INTRAVENOUS	50 mg in 1 1	9/6/2022

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
Kengrexal	Chiesi Farmaceutici S.p.A.,Via Palermo 26/A,43122 Parma,Italy	Authorised	3/23/2015
Kengrexal	Chiesi Farmaceutici S.p.A.,Via Palermo 26/A,43122 Parma,Italy	Authorised	3/23/2015

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

AI-Powered Research

Premium Access